O
O. F. Ballester
Researcher at University of South Florida
Publications - 33
Citations - 2414
O. F. Ballester is an academic researcher from University of South Florida. The author has contributed to research in topics: Multiple myeloma & Chemotherapy. The author has an hindex of 15, co-authored 33 publications receiving 2391 citations. Previous affiliations of O. F. Ballester include University of California, Los Angeles.
Papers
More filters
Journal ArticleDOI
Efficacy of Pamidronate in Reducing Skeletal Events in Patients with Advanced Multiple Myeloma
James R. Berenson,Alan Lichtenstein,Lester Porter,Meletios A. Dimopoulos,Roldolfo Bordoni,Sebastian George,Allan Lipton,Alan Keller,O. F. Ballester,Michael J. Kovacs,Hilary A. Blacklock,Richard Bell,Joseph F. Simeone,Dirk J. Reitsma,Maika Heffernan,John J. Seaman,Robert Knight +16 more
TL;DR: Monthly infusions of pamidronate provide significant protection against skeletal complications and improve the quality of life of patients with stage III multiple myeloma.
Journal ArticleDOI
Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group.
James R. Berenson,Alan Lichtenstein,Lester Porter,Meletios A. Dimopoulos,Roldolfo Bordoni,Sebastian George,Alan Lipton,Alan Keller,O. F. Ballester,Michael J. Kovacs,Hillary Blacklock,Richard Bryan Bell,Joseph F. Simeone,Dirk J. Reitsma,Maika Heffernan,John J. Seaman,Rob Knight +16 more
TL;DR: Long-term monthly infusions of pamidronate as an adjunct to chemotherapy are superior to chemotherapy alone in reducing skeletal events in stage III multiple myeloma patients, and may improve the survival of patients on salvage therapy.
Journal ArticleDOI
Multicenter phase III trial to evaluate CD34(+) selected versus unselected autologous peripheral blood progenitor cell transplantation in multiple myeloma.
Robert Vescio,Gary J. Schiller,A. Keith Stewart,O. F. Ballester,Stephen J. Noga,Hope S. Rugo,Cesar O. Freytes,Edward A. Stadtmauer,Stefano R. Tarantolo,Firoozeh Sahebi,Patrick J. Stiff,Jacinta Meharchard,Robert L. Schlossman,Randy A. Brown,Heather Tully,Mark C. Benyunes,Cindy Jacobs,Ronald J. Berenson,John F. DiPersio,Kenneth C. Anderson,James R. Berenson +20 more
TL;DR: This phase III trial demonstrates that CD34-selection of peripheral blood progenitor cells significantly reduces tumor cell contamination yet provides safe and rapid hematologic recovery for patients receiving myeloablative therapy.
Journal ArticleDOI
Maximum-tolerated doses of ifosfamide, carboplatin, and etoposide given over 6 days followed by autologous stem-cell rescue: toxicity profile.
Karen K. Fields,Gerald J. Elfenbein,Hillard M. Lazarus,Brenda W. Cooper,Janelle Perkins,Richard J. Creger,O. F. Ballester,John H. Hiemenz,William E. Janssen,Zorsky Pe +9 more
TL;DR: ICE is well tolerated, with acceptable hematopoietic side effects and predictable organ toxicity, and the dose-limiting toxicities of ICE were CNS toxicity and acute renal failure.
Journal ArticleDOI
High-dose chemotherapy and autologous peripheral blood stem cell transplantation in patients with multiple myeloma and renal insufficiency.
O. F. Ballester,R Tummala,William E. Janssen,Karen K. Fields,John W. Hiemenz,Steven C. Goldstein,Janelle Perkins,Daniel M. Sullivan,Raquel Rosen,Robert Sackstein,Zorsky Pe,R. A. Saez,G. J. Elfenbein +12 more
TL;DR: High-dose therapy with BUCY and autologous peripheral blood stem cell rescue is feasible in patients with multiple myeloma and renal failure and two patients have remained in complete remission for 28 and 39 months.